

Figure S1 Differences in preoperative and postoperative day 1 laboratory indicators. *, statistical significance was set at $P < 0.05$. TP, total protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; Glu, blood glucose; UA, blood uric acid; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; BUN, blood urea nitrogen; CRE, creatinine, TBIL, total bilirubin. BF, before operation; AF1, after operation day one.

Table S1 Basic characteristics of patients with chylothorax (n=42)

No.	Sex	Age (years)	Lobectomy site	Surgical procedure	Pathological type	Mediastinal lymph node group	Number of positive lymph nodes cleared/all lymph nodes cleared	TNM stage	Diagnosis to discharge date, day	Treatment method	Readmission and reintervention	Outcome
1	M	61	RUL + RML + RLL	L + W + W	LUAD	2+4+7	0/9	T1bN0M0	10	Surgery	-	Improvement
2	M	50	LLL	L	LUAD	2+3+4+7+9	0/20	T1cN0M0	7	Fat-free diet + SST	-	Improvement
3	M	70	RML + RLL	L + L	LUSC	2+3+4+7+9	0/46	T1bN0M0	17	Medication adherence	-	Improvement
4	M	62	RUL	L	LUAD	2+4+7	0/24	T1aN0M0	4	Fat-free diet	-	Improvement
5	F	68	RLL	L	Benign	2+4+7+8+9	0/15	/	4	Fasting + PN	-	Improvement
6	M	62	RLL	L	LUSC*	-	0/2	T1cN0M0	15	Fasting + PN	Repeat thoracentesis	Improvement
7	M	68	RLL	L	LUSC	-	0/2	TxN0M0	23	Fasting + PN	-	Improvement
8	F	47	RUL	S	LUAD	2+4+7+9	0/19	T1aN0M0	5	Fat-free diet	-	Improvement
9	F	48	RLL	L	LUAD	2+4+7+9	1/14	T1bN0M0	6	Fasting + PN	-	Improvement
10	F	50	LLL	L	LUAD	4+5+7	5/11	T1bN1M0	8	Fasting + PN + SST	Readmission & repeat thoracentesis	Improvement
11	F	32	LUL	W + MSS	LUAD	-	0/0	T1aN0M0	10	Fasting + PN	-	Improvement
12	F	60	RUL	L	LUAD	2+4+7	0/24	T1aN0M0	15	Surgery	-	Improvement
13	F	37	RUL	S	LUAD	2+4+7	0/24	T1aN0M0	4	Fat-free diet	-	Improvement
14	M	54	LUL	L	LUAD	5+7	0/15	T1bN0M0	23	Fat-free diet	-	Death
15	M	62	RLL	L	LUAD	2+4+7	0/10	T1bN0M0	9	Fasting + PN	-	Improvement
16	M	52	LUL	L	LUSC	4+5+6+7+8+9	1/26	T1bN1M0	7	Medication adherence	-	Improvement
17	M	49	LUL + LLL	S + W	LUAD	5+7+9	0/13	T1bN0M0	2	Fat-free diet	-	Improvement
18	M	53	RUL	L	LUSC	2+4+7	1/16	T2aN1M0	6	Fasting + PN	-	Improvement
19	F	63	RUL + RML	L + W	LUAD	2+4+7	0/9	T1bN0M0	12	Medication adherence	-	Improvement
20	F	59	RUL	L	LUAD	2+4+7	0/34	T1bN0M0	9	Medication adherence	-	Improvement
21	F	69	RLL	L	LUAD	4+7+9	0/13	T1bN0M0	23	Surgery	-	Improvement
22	M	65	RML + RLL	L	LUAD*	2+4+7+9	3/39	T2bN1M0	39	Surgery	Reoperation	Improvement
23	M	57	RUL + RLL	W + L	LUAD	2+4+7+9	0/12	T1cN0M0	23	Surgery	Repeat thoracentesis	Improvement
24	F	59	LLL	L	LUAD	4+5+7+8+9	0/28	T1bN1M0	19	Surgery	-	Improvement
25	M	67	RUL	L	LUSC	2+4+7	0/44	T1bN0M0	6	Fasting + PN + SST	-	Improvement
26	M	56	LUL	L	LUSC	5+7	1/10	T1cN1M0	7	Fasting + PN	Repeat thoracentesis	Improvement
27	M	55	RLL	L	LUSC	2+4+7+9	0/20	T2aN0M0	7	Fasting + PN + SST	-	Improvement
28	F	65	RML + RLL	W + L	LUAD	2+3+4+7+9	0/31	T1cN0M0	9	Fasting + PN + SST	-	Improvement
29	M	64	RUL	L	LUSC	2+4+7	6/22	T3N2M0	10	Surgery	-	Improvement
30	F	63	RLL	W	LUAD	2+4+7	0/16	T1aN0M0	13	Surgery	Repeat thoracentesis	Improvement
31	M	58	RUL + RML + RLL	S + W + W	LUAD	2+4+7	0/12	T1bN0M0	11	Fasting + PN + SST	-	Improvement
32	F	75	RUL + RLL	W + W	LUAD	2+4+7+8+9	0/7	T1bN0M0	4	Fasting + PN + SST	-	Improvement
33	M	60	RUL + RLL	L + S	LUAD*	2+3+4+7	15/21	T1bN2M0	16	Fasting + PN + SST	-	Death
34	M	67	LLL	L	LUAD	4+5+7+9	0/17	T1bN0M0	4	Fasting + PN	-	Improvement
35	M	56	RUL	L	Benign	2+4+7	0/15	/	16	Surgery	Repeat thoracentesis	Improvement
36	F	61	RUL	W	LUAD	2+4+7	0/19	T1bN0M0	10	Medication adherence	-	Improvement
37	M	58	RUL	L	LUAD*	2+4+7	0/17	T1bN0M0	11	Fasting + PN	-	Improvement
38	M	67	RLL	L	LUAD	2+4+7	0/11	T1bN0M0	7	Fasting + PN	-	Improvement
39	M	65	LUL	L	LUSC*	7	0/12	T4N0M0	13	Medication adherence	-	Improvement
40	M	53	RUL + RLL	W + W	LUAD	7	0/7	T1bN0M0	9	Fasting + PN	-	Improvement
41	M	78	RML + RLL	W + W	LUSC	-	-	T1cN0M0	11	Fasting + PN	-	Improvement
42	M	68	RUL	L	LUSC	2+4+7	0/16	T2aN0M0	11	Fasting + PN	-	Improvement

*, the postoperative pathological results indicate a composite carcinoma with the presence of other concurrent malignant tumors. M, male; F, female; LUL, left upper lung; LLL, left lower lung; RUL, right upper lung; RML, right middle lung; RLL, right lower lung; W, wedge resection; S, lobectomy; L, pneumonectomy; MSS, mediastinal surgery; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; mediastinal lymph node group: 2, upper paratracheal nodes; 3, prevascular and retrotracheal nodes; 4, lower paratracheal nodes; 5, subaortic nodes; 6, paraaortic nodes; 7, subcarinal nodes; 8, paraesophageal nodes; 9, pulmonary ligament nodes; PN, parenteral nutrition; SST, somatostatin; TNM, tumor, node, metastasis.




Figure S2 The line graph of postoperative drainage volume for 4 characteristic cases. These include the following typical cases: chemical pleurodesis (Case 3), improvement after conservative treatment (Case 7), VATS thoracic duct ligation (Case 12), and chylothorax with severe postoperative complications (Case 33).